The HDAC Inhibitor Butyrate Impairs β Cell Function and Activates the Disallowed Gene Hexokinase I

Histone deacetylase (HDAC) inhibitors such as butyrate have been reported to reduce diabetes risk and protect insulin-secreting pancreatic β cells in animal models. However, studies on insulin-secreting cells in vitro have found that butyrate treatment resulted in impaired or inappropriate insulin s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridgeman, Stephanie, Ellison, Gaewyn, Newsholme, Philip, Mamotte, Cyril
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705743/
https://www.ncbi.nlm.nih.gov/pubmed/34948127
http://dx.doi.org/10.3390/ijms222413330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705743/
https://www.ncbi.nlm.nih.gov/pubmed/34948127
http://dx.doi.org/10.3390/ijms222413330

Ejemplares similares